Treace Medical Concepts Inc

Treace Medical Concepts announced it will highlight multiple new product innovations and present clinical data at the American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle from September 16-19, 2026. The new offerings extend the company's bunion market leadership and accelerate penetration into new foot and ankle market adjacencies, according to CEO, Founder and Chairman John T. Treace. Among the featured technologies are the Lapiplasty Lightning System, the Tailorplasty MIS Tailor's Bunion System for minimally invasive treatment of tailor's bunions estimated to affect approximately 5-10% of the adult population, and the Treace X-ray App for radiographic measurements. New products aimed at the mid and hindfoot markets include SuperBite Fully-Threaded Compression Screws, the HyperPlate XM Dynamic Compression Locking Implant, CartiBlaster Powered Joint Prep instruments, and the VitaFuse Bioactive Glass Graft. Clinical results from the landmark 5-year ALIGN3D Lapiplasty, MTA3D Adductoplasty and SPRINT SpeedPlate studies will be presented during the meeting, with the ALIGN3D podium presentation set for Friday, September 18 at 8:45am PST by Daniel Farber, MD, of Lehigh Valley Orthopedic Institute.

Several biotech stocks surged on Tuesday, led by Boundless Bio which agreed to an all-stock merger with privately held Serapha Bio. Boundless Bio expects to declare a cash dividend to pre-merger stockholders before the deal closes in the fourth quarter of 2026, after which the combined company will operate as Serapha Bio and trade on Nasdaq under the ticker AATD. Monopar Therapeutics rose over 19% with its New Drug Application for ALXN1840 in Wilson disease on track for mid-2026 submission to the FDA. Galectin Therapeutics gained over 11% after reaching an agreement with the FDA on key elements of its planned Phase 3 program for Belapectin in MASH cirrhosis with portal hypertension, with the final protocol expected in the third quarter of 2026. Other notable movers included Jade Biosciences, up nearly 13% amid progress in its autoimmune pipeline, and Treace Medical Concepts, up almost 12% following the first surgical use of its HyperPlate XM implant.